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ARTICLE
Neoadjuvant anti-OX40 (MEDI6469) therapy
in patients with head and neck squamous cell
carcinoma activates and expands antigen-specific
tumor-infiltrating T cells
Rebekka Duhen 1✉, Carmen Ballesteros-Merino1, Alexandra K. Frye 1, Eric Tran 1,
Venkatesh Rajamanickam 1, Shu-Ching Chang2, Yoshinobu Koguchi1, Carlo B. Bifulco1,3, Brady Bernard1,
Rom S. Leidner 1, Brendan D. Curti1, Bernard A. Fox1, Walter J. Urba1, R. Bryan Bell 1 &
Andrew D. Weinberg 1,4✉
Despite the success of checkpoint blockade in some cancer patients, there is an unmet
need to improve outcomes. Targeting alternative pathways, such as costimulatory molecules
(e.g. OX40, GITR, and 4-1BB), can enhance T cell immunity in tumor-bearing hosts. Here we
describe the results from a phase Ib clinical trial (NCT02274155) in which 17 patients
with locally advanced head and neck squamous cell carcinoma (HNSCC) received a murine
anti-human OX40 agonist antibody (MEDI6469) prior to definitive surgical resection. The
primary endpoint was to determine safety and feasibility of the anti-OX40 neoadjuvant
treatment. The secondary objective was to assess the effect of anti-OX40 on lymphocyte
subsets in the tumor and blood. Neoadjuvant anti-OX40 was well tolerated and did not delay
surgery, thus meeting the primary endpoint. Peripheral blood phenotyping data show
increases in CD4+ and CD8+ T cell proliferation two weeks after anti-OX40 administration.
Comparison of tumor biopsies before and after treatment reveals an increase of activated,
conventional CD4+ tumor-infiltrating lymphocytes (TIL) in most patients and higher
clonality by TCRβ sequencing. Analyses of CD8+ TIL show increases in tumor-antigen
reactive, proliferating CD103+ CD39+ cells in 25% of patients with evaluable tumor tissue
(N= 4/16), all of whom remain disease-free. These data provide evidence that anti-OX40
prior to surgery is safe and can increase activation and proliferation of CD4+ and CD8+
T cells in blood and tumor. Our work suggests that increases in the tumor-reactive CD103+
CD39+ CD8+ TIL could serve as a potential biomarker of anti-OX40 clinical activity.
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Head and neck squamous cell carcinoma (HNSCC) is theseventh most common cancer worldwide and is char-acterized by a high rate of therapeutic resistance1–3.
Recurrence rates are ~50% in locally advanced HNSCC4, despite
aggressive treatment involving surgery, radiation, and che-
motherapy. Checkpoint inhibitor (CI) antibodies targeting pro-
grammed cell death protein 1 (PD-1) or programmed death
ligand-1 (PD-L1) have improved overall survival for patients with
metastatic HNSCC, and have been FDA approved in conjunction
with chemotherapy as first-line treatment. However, only 10–20%
of patients benefit from PD-1/PD-L1 blockade5–8.
Neoadjuvant immunotherapy improved survival compared to
adjuvant treatment in preclinical models9 and a number of
investigators are currently testing CI’s in the neoadjuvant setting
for the treatment of HNSCC (NCT02296684, Ravindra Uppaluri;
NCT02764593, Robert Ferris). Feasibility and safety of check-
point blockade prior to surgery have been demonstrated clinically
in urothelial carcinoma of the bladder10, resectable non-small cell
lung cancer (NSCLC) independent of PD-L1 expression11, stage
III/IV melanoma12,13, and glioblastoma multiforme (GBM)14–16.
Interestingly, in melanoma, neoadjuvant treatment with anti-PD-
1 results in major pathologic responses and brisk TIL infiltration
that correlates with disease-free survival17.
The role of immune costimulatory agonist agents in the
neoadjuvant setting in cancer patients has not been previously
investigated. This is the first report of a human T-cell agonist
antibody specific for OX40 administered in the neoadjuvant
setting. OX40 (CD134), a member of the tumor necrosis factor
receptor superfamily, is part of a potent costimulatory pathway
that can enhance T-cell memory, proliferation, survival, and anti-
tumor activity18–21. In contrast to other costimulatory molecules,
such as CD27 and CD28, OX40 is absent on resting naïve and
memory T cells, and induced only after T-cell receptor (TCR)
engagement22. Immune profiling studies comparing TIL and
peripheral blood from patients with HNSCC demonstrated
expression of OX40, as well as PD-1 and CTLA-4, on T cells
isolated from the tumor compared to blood, suggesting that
targeting these pathways independently or in combination may
result in therapeutic advantages23. A first in human phase I
clinical trial with this antibody to OX40 (MEDI6469) demon-
strated acceptable toxicity, increased proliferation of both CD4+
and CD8+ T cells, and led to regression of at least one metastatic
lesion in 12 of 30 patients treated24. Our laboratory has also
demonstrated that anti-OX40 treatment reduces recurrences
when given prior to surgery in murine models25. Altogether, these
results suggested that delivering anti-OX40 prior to surgery in
HNSCC patients may confer clinical benefit. Furthermore, this
presents an ideal opportunity to analyze the immune effects of
anti-OX40 therapy in the tumor.
Here, we show that administering an anti-OX40 antibody at
various intervals prior to definitive surgical resection in 17 patients
with stage II-IVA HNSCC (Clinical Trial ID#NCT02274155) is
safe. The optimal immunologic activation occurs 2 weeks after
anti-OX40 administration in the tumor and periphery. Immune
monitoring using flow cytometry, quantitative multiplex immu-
nochemistry (mIHC), and TCR sequencing to interrogate the
effects of anti-OX40 in the tumor, suggests that increases in the
tumor-reactive CD8+ TIL population may serve as a biomarker of
clinical activity.
Results
Neoadjuvant anti-OX40 treatment in patients with HNSCC is
safe. Between December 2014 and April 2017, 17 of 19 patients
who were consented and assessed for eligibility were enrolled in
the trial and received anti-OX40 at 0.4 mg/kg on days 1, 3, and 5
(Fig. 1a and Supplementary Data 1 for the study protocol). Three
patients were enrolled into cohort 1 (day 8 surgery), nine patients
were in cohort 2 (day 12 surgery), four patients were in cohort 3
(day 19 surgery), and one patient was enrolled at day 26, a time
point that was removed from the protocol subsequently (Sup-
plementary Table 1a). The average age was 60 years (SD ± 8.9
years) and clinical staging based on the American Joint Com-
mittee on Cancer (AJCC) 7th edition ranged from stage II to
IVA disease; tumors involved the oral cavity (N= 6), oropharynx
(N= 9), hypopharynx (N= 1), or larynx (N= 1)26 (Supplemen-
tary Table 1a, b). Tumor HPV status, assessed by p16 IHC testing,
was diffusely positive in six of nine oropharyngeal tumors and the
remainders were negative. All patients underwent definitive sur-
gical resection, neck dissection, appropriate reconstruction, and
pathologic risk-adapted adjuvant radiation or chemoradiation per
standard of care. Three patients had prior radiation therapy
related to their cancer. All other patients were treatment naive
(Supplementary Table 1b). In 16 of 17 patients, a tumor biopsy
specimen was obtained prior to treatment, and at the time of
definitive surgery, the primary tumor was collected as well as
metastatic and draining lymph node(s) in some patients. PBMC
were collected before and after treatment in all patients.
Anti-OX40 was well-tolerated and did not delay or cause
toxicity prior to surgery. There were no grade III or IV adverse
events (AE) due to anti-OX40 (Supplementary Table 2). Grade III
or IV surgical complications, as assessed by the Clavien–Dindo
classification, occurred in 29% (N= 5) of patients, which
included a non-ST elevated myocardial infarction (managed with
stent placement), sepsis, and cellulitis (managed successfully with
antibiotics), and acute respiratory failure (managed uneventfully),
none of which were attributed to anti-OX40 administration
(Supplementary Table 3). One patient developed meningitis
postoperatively, which resolved with antibiotics and steroids. In
general, the spectra of toxicities observed in this trial were similar
to what was reported in the first in human trial, together with
lymphopenia in most patients24. Complete blood counts (CBC)
revealed transient lymphopenia along with higher neutrophil
counts in all patients, potentially due to migration of lymphocyte
subsets into lymphoid organs and tissues followed by a rebound
(Fig. 1b and Supplementary Fig. 1a). Lymphocyte counts showed
the greatest decrease (by fold change) in D12 patients, and
neutrophil counts were highest in patients that underwent
surgery at D19. Taken together, anti-OX40 administration was
safe and well-tolerated in all patients enrolled in the trial, with
transient lymphopenia 2 weeks following antibody infusion.
T-cell proliferation in peripheral blood following anti-OX40
administration peaks between D12 and D19. Immune activa-
tion was investigated by assessing phenotypic changes in PBMC
at different timepoints following anti-OX40 administration
(baseline, day of surgery, day 34, and day 55; Supplementary
Fig. 2a, b). The change in percentage of conventional CD4+
(Tconv), CD8+, and Foxp3+ (Treg) cells in patients was ana-
lyzed over time, but no significant changes were observed in these
subsets in the D8, D12, or D19 cohorts. The percentage of Treg
cells increased slightly after anti-OX40 in both the D12 and D19
cohorts (Fig. 1c and Supplementary Fig. 1b), albeit not sig-
nificantly (P= 0.0585, D12; P= 0.0525, D19). Using Ki-67 as a
proliferation marker, we detected an increase in proliferation
between baseline and D12 and D19 in CD4+ Tconv cells (P=
0.0074, D12; P= 0.0015, D19) as was observed in the initial phase
I clinical trial using MEDI646924 (Fig. 1d and Supplementary
Fig. 1c, f). We did not observe a correlation between baseline and
day of surgery (DOS) OX40 expression by Tconv CD4+ cells and
immune activation/proliferation after anti-OX40 administration
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(Supplementary Fig. 1d), and OX40 expression was unchanged
during the course of the 2-month monitoring (Supplementary
Fig. 1e). Proliferation also increased in Foxp3+ Treg cells, albeit
at a lower level (2.6-fold) compared to conventional CD4+ T cells
(Tconv), which increased 6.8-fold in the D12 cohort. Proliferation
of CD8+ TEMRA- and effector memory CD45RA+ (TEMRA+)
T cells consistently peaked with a four- to sixfold increase
between D12 and D19 (Fig. 1d and Supplementary Fig. 1f) (P=
0.0154 TEMRA−, P= 0.0016 TEMRA+, D12; P= 0.0398
TEMRA−, P= 0.12 TEMRA+, D19), while the frequencies of
each of these subsets remained constant during the time mon-
itored (Fig. 1e and Supplementary Fig. 1g). The percentage of B
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lymphocytes was reduced marginally at D8 and D12, reflecting
the lymphopenia that we observed, but was at baseline level by
D19 after anti-OX40 administration (Fig. 1f, first panel). In
parallel, albeit B-cell frequencies dropped slightly, Ki-67+ CD19
+ cells were increased in the D12 cohort with a fivefold increase
(P= 0.0067), and the CD38hi CD19+ B-cell subset (plasmablasts)
increased tenfold by D12 (P= 0.0107) (Fig. 1f and Supplementary
Fig. 1h). Together, these observations show evidence of sig-
nificantly increased immune activation in most patients at D12
(and in some patients at D19) after anti-OX40, although
increased B-cell proliferation could be due to initiation of a
human anti-mouse antibody immune response (to MEDI6469),
which was observed in our phase I study24. Lastly, expression of
the activation marker inducible T-cell costimulatory (ICOS)
protein was upregulated on CD4+ Tconv cells at D12 and D19
after anti-OX40 treatment (P= 0.0066, D12; P= 0.0234, D19) as
well as on Treg cells in the D12 cohort (P= 0.0085, D12; P=
0.2289, D19) (Fig. 1g). These data indicate that anti-OX40
increased both activation and proliferation of peripheral CD4+
and CD8+ T cells 12 and 19 days after its administration in
HNSCC patients.
Anti-OX40 alters the composition of T-cell subsets within the
tumor. Diagnostic biopsies and surgical resection samples from
16 out of 17 patients were assessed for changes in TIL before and
after anti-OX40 (Supplementary Fig. 3). Multicolor flow cyto-
metry analysis revealed an increase in the percentage of CD8+
T cells with a concomitant decrease of CD4+ T cells in the TIL
from 5 out of 16 patients after anti-OX40 treatment. Of note,
Treg cells calculated as a percentage of total CD4+ T cells also
increased after anti-OX40 in the same patients that showed
increases in CD8+ T cells (Fig. 2a). Recently we reported that
CD8+ TIL can be divided into three subsets based on expression
of CD103 and CD39: CD103−CD39− double negative (DN),
CD103+ CD39− single-positive (SP), and CD39+ CD103+
double-positive (DP) cells. DP CD8+ TIL are enriched for tumor
reactivity, have a resident memory signature, and are present at
low frequencies in the blood27. tSNE analysis of CD3+ cells
within the TIL of pre- and post samples in a representative D12
patient, HNOX07, showed a distinct cluster of CD8+ cells that
co-expressed CD103, CD39, and Ki-67, and this cluster was
increased after anti-OX40 administration (Fig. 2b). Figure 2c
shows a dot plot of CD103 and CD39 expression pre- and post
anti-OX40 treatment on CD4+, CD8+, and Treg cells in the
same patient (HNOX07). Supplementary Fig. 4a shows another
patient with an increase in the DP CD8+ TIL subset after anti-
OX40 treatment and a patient with low expression of this subset
in the tumor, which remained unchanged after anti-OX40
treatment (Supplementary Fig. 4b, c). The expression of CD103
and CD39 in CD8+ TIL and CD39 in CD4+ TIL before and after
anti-OX40 for all patients is summarized in Fig. 2d. We also
analyzed the expression of Ki-67 in the tumor before and after
treatment. A representative patient (HNOX04) is shown in Fig. 2e
where Ki-67+ CD4+ TIL were increased after treatment, while,
among CD8 TIL subsets, DP cells showed the highest increase in
proliferation. A significant increase in Ki-67 expression was
observed in the Tconv CD4+ TIL (11 of 16 patients). Increased
CD8+ TIL proliferation post treatment was observed in 4 of 16
patients in the CD103+ CD39+ CD8+ TIL sub-population,
while one patient showed an increase in Ki-67 expression in the
SP subset.
A CD8 TIL activation index to quantify immunological
changes after anti-OX40. In the anti-OX40 phase I study, we
found a correlation between increased CD8+ T-cell proliferation
and patients with regressing or stable disease24. In mouse models,
we also described an increase in CD8+ TIL after anti-OX40
treatment28, therefore we performed an in-depth analysis on CD8+
TIL before and after anti-OX40. Based on changes in the percentage
of CD8+ TIL after anti-OX40 administration (increase in 5/16
patients), changes in CD103/CD39 expression on CD8+ TIL
(increase in 8/16 patients), and proliferative changes in CD8+ TIL
(Ki-67 expression increased in 4/16), we calculated an activation
index based on the fold-change values comparing percentages at the
DOS to baseline. All three categories combined were used to define
patients with robust changes in CD8+ TIL (Supplementary Fig. 5a).
Using these criteria, four patients showed robust activation in CD8
+ TIL and were deemed “immunologic responders”, two of which,
HNOX04 and HNOX07, experienced a profound increase in this
population post treatment (Fig. 3a). We also investigated whether
the activation in the periphery would reflect increases in the tumor.
Both, ICOS and Ki-67/CD38 were upregulated on peripheral Tconv
CD4+ cells between D12 and D19 but did not segregate responders
from non-responders. (Supplementary Fig. 5b). We believe that the
increase in proliferating DP TIL represents robust activation of the
tumor-reactive CD8+ TIL in 4 of 16 patients.
In order to examine whether anti-OX40 treatment affected the
immune cell distribution in the tumor microenvironment, we
analyzed FFPE patient samples pre- and post anti-OX40
treatment using mIHC. We first analyzed the expression of
CD3, CD8, Foxp3, PD-L1, and CD163 to examine changes in
T-cell subsets, PD-L1 expression, and presence of CD163+
macrophages after OX40 treatment. In line with published data29,
total CD3+, CD3+ Foxp3+, and CD3+ CD8+ T-cell numbers
were significantly higher in the stroma of most HNSCC patients
compared to the tumor, which was observed before and after
anti-OX40 treatment (Fig. 3b and Supplementary Fig. 5c). We
compared the number of CD163+ tumor-associated macro-
phages and PD-L1 expression in tumor versus stromal areas and
found minimal changes in these subsets (Supplementary Fig. 3d).
Fig. 1 Immune activation after OX40 administration in head and neck squamous cell carcinoma (HNSCC). Patients with HNSCC cancer were given three
doses of neoadjuvant anti-OX40 (MEDI6469) at 0.4mg/kg, followed by resection at days 8, 12, or 19. a Trial schema of administration of anti-OX40 in the
neoadjuvant setting in patients with HNSCC. b Blood lymphocyte and neutrophil counts were assessed at baseline, day of surgery (D8, D12, or D19), D34,
and D55. The mean+ SEM of the absolute cell counts per liter are shown for each subset. c–e Change in percentages of viable, CD3+ T cells. The gating
strategy is outlined in Supplementary Fig. 2a, b. c Average percentages of CD4+ Tconv, CD8+, and CD4+ Treg cells during and after anti-OX40
administration measured by flow cytometry. d Summary of the average percentage of Ki-67 expression during OX40 treatment in CD4+ Tconv memory
cells, CD4+ Treg cells, CD8+ TEM RA−, and TEM RA+ cells. e Average percentages of CD8+ TEMRA− and CD8+ TEMRA+ cells during and after anti-OX40
administration. f Summary of the percentages of total CD19+ cells, Ki-67+ CD19+ cells and plasmablasts, identified by the absence of IgD and expression
of CD38. g Expression of ICOS on CD4+ Tconv and Treg cells during and after OX40 treatment. All cells were gated excluding doublets and dead cells.
Error bars indicate mean+ SEM (c–g); *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns not significant. P values were determined by paired two-tailed
Student’s t test between D1 and D12 or D19. N= 3 patients in the D8 cohort, N= 9 patients in the D12 cohort, and N= 4 patients in the D19 cohort (b–g).
Black triangles represent the D8, orange circles the D12, and blue squares the D19 cohort. The same color code is applied to the values denoting
significance. Source data are provided as Source Data file.
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Of note, the number of CD3+ cells expressing PD-L1 in the
stroma was reduced markedly after anti-OX40 administration
(Supplementary Fig. 5d). We then analyzed stroma and tumor in
all patients for CD3, CD8, Ki-67, and CD103. CD39 was not
assessed because there is currently not a suitable antibody for
IHC staining. Figure 3c depicts tumor specimens from two
representative HPV+ patients; one patient (HNOX18, top)
showed an increase in cells expressing CD8, CD103, and Ki-67
in the intratumoral areas after anti-OX40 treatment, whereas
HNOX09 (bottom) showed no changes in stroma or tumor after
treatment. Similar observations were made in HPV− patients;
increased immune infiltrates were observed in some patients
Fig. 2 Changes in TIL composition after OX40 administration. TIL from a pretreatment biopsy and a surgical specimen after OX40 therapy were
assessed for lymphocyte composition and activation markers. The gating strategy is outlined in Supplementary Fig. 3. a Percentages of CD4+ Tconv cells,
CD4+ Treg cells, and CD8+ T cells in each patient before and after OX40 administration, N= 17 patients. b tSNE analysis of the pre and post specimens
from patient HNOX07, gated on CD3+ cells. Blue represents the baseline sample, orange the day of surgery sample and gray is the concatenated file. The
red circle indicates the population of cells expressing both CD103 and CD39. tSNE analysis was performed on N= 4 patients, one representative patient is
shown here, two more patients are shown in Supplementary Fig. 4. c Flow cytometric analysis of the expression of CD103 and CD39 in CD4+ Tconv cells,
CD8+ cells, and CD4+ Treg cells in one immune-responding head and neck squamous cell carcinoma (HNSCC) patient pre- and post OX40 therapy.
d Summary of the flow cytometric analysis in (c), left panel depicts CD8+ CD103+ CD39+ T cells and the right panel depicts CD4+ CD39+ T cells;
patients with an increase are shown on the left, patients with a decrease are on the right. e Expression of Ki-67 was assessed among memory CD4+ TIL
and CD8+ TIL subsets (DN, SP, and DP) in biopsy (pre) and DOS (post) tissue (N= 17 patients). Blue histograms indicate pre, red indicate post tissues.
The left graph shows a summary of the percentage of proliferating CD8+ T-cell subsets pre- and post anti-OX40 in each patient. The graph on the right
indicates the expression of Ki-67 in CD4+ TIL pre- and post anti-OX40. Red symbols highlight patients that exhibit an increase. *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001; ns not significant. P values were determined by paired two-tailed Student’s t test between pre- and post samples (a, e).
Source data are provided as Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21383-1 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:1047 | https://doi.org/10.1038/s41467-021-21383-1 | www.nature.com/naturecommunications 5
Fig. 3 Multiplex IHC analysis reveals changes in lymphocyte infiltrates in tumor and stroma after anti-OX40. Multiplex IHC was performed on FFPE
specimens from N= 15 patients to determine the composition and changes of the immune infiltrate in tumor and stroma. For each patient, on each slide,
six regions of interest (ROI) were analyzed for tumor and stroma. a Fold change of CD8+ CD103+ CD39+ Ki-67+ T cells for all patients as determined by
flow cytometric analysis. Filled orange circles indicate patients with an activation index above 1. Filled black circles indicate patients with an activation index
below 1. IR immune responder, INR immune non-responders. b Total number of CD3+ and Foxp3+ T cells among tumor and stroma in N= 15 patients pre-
and post anti-OX40. Error bars indicate mean ± SEM, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns not significant. P values were determined by
paired two-tailed Student’s t test between pre and post samples and between tumor and stroma. c, d Representative multiplex IHC of two HPV+ (c) and
two HPV− (d) head and neck squamous cell carcinoma (HNSCC) patients pre and post anti-OX40, identified by the response (IR and INR) as determined
in (a). eMagnified view (bottom) of cells expressing CD8, CD103, and Ki-67 in the tumor area (top). f Summary of the numbers of Ki-67+ CD103+ CD8+
cells in the tumor and stroma pre- and post anti-OX40, in patients stratified by the immunologic response. N= 4 IR, N= 10 INR. Error bars indicate mean ±
SEM. The values presented in (b) and (f) represent the mean of the ROI analysis for each patient. g Comparison of the numbers of Ki-67+ CD103+ CD8+
cells enumerated by multiplex IHC in the tumor and stroma, with the percentages of the same subset determined by flow cytometry. Black dots represent
the immune non-responders. Red dots represent the immune responders. Source data are provided as Source Data file.
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(HNOX04, top); with little to no change in other patients after
anti-OX40 (HNOX14, bottom) (Fig. 3d). Figure 3e is a high-
power image of T cells expressing CD8, CD103, and Ki-67 within
the tumor, which we believe represent the proliferating CD103+
CD39+ CD8+ TIL. When flow cytometry data were analyzed
after grouping patients according to immunologic responders
(IR) versus non-responders (INR) (Fig. 3a), we observed that the
increase in proliferating Ki-67+ CD103+ CD8+ CD3+ T cells
was largely confined to the intratumoral compartment rather
than the stroma in the four responding patients (tumor: 3.4-fold
increase ±2.04, vs stroma: 1.12 ± 0.78) (Fig. 3f and Supplementary
Fig. 5e). Finally, we compared whether the frequencies of DP
CD8+ TIL obtained by flow cytometry correlated with observa-
tions by IHC and if so, whether there was any difference between
IHC data obtained from within the tumor or stroma. The flow
cytometry data correlated well with cell counts obtained from
intratumor areas (R2= 0.5776), but not as well with cell counts
in the stroma (R2= 0.00046) (Fig. 3g). Together, these data
suggest that in some patients CD103+ CD39+ CD8+ TIL are
preferentially expanded and/or recruited into the tumor areas
after anti-OX40, potentially limiting tumor growth.
Survival analysis after neoadjuvant anti-OX40. The median
follow-up time for this group of patients is 39 months (95% CI:
34–45 months)30. The overall and disease-free survival for the
entire study population was 94 and 71% at 1.5 years and 82 and
71% at 3 years, respectively (Fig. 4a Supplementary Table 4a).
Figure 4a and Supplementary Table 4b indicate the number of
patients at risk for the Kaplan–Meier curve31. Five of 17 patients
have recurred, two of which remain alive with stable disease, and
are currently being treated with various immunotherapy and
conventional treatment regimens. When we segregated patients
into immunologic responders and non-responders as defined in
Fig. 3a, it was noted that all four immunologic responders
are alive without recurrence, despite having the high-risk disease
(3/4 immunologic responders were HPV−) (Fig. 4b). Of the 6
HPV+ patients, only one has recurred, whereas 4 of 11 (36%)
HPV− patients recurred after surgery, which is lower than the
expected recurrence rate in this population of locoregionally
advanced patients (50–65%)32.
Effects of anti-OX40 on T-cell clones in tumor and blood. To
better understand the molecular characteristics of T cells in the
tumor after anti-OX40 administration, we performed high-
throughput TCRβ sequencing analysis on selected patients,
where sufficient tissue was available. In other studies, T-cell
receptor repertoires were assessed in total TIL populations, often
isolated from FFPE samples, which does not distinguish the
source of the TCR sequences found within the tumor (e.g., Tconv
CD4+, Treg CD4+, CD8+, or natural killer T cells). We ana-
lyzed the TCRβ repertoire in both blood (pre- and post anti-
OX40) and TIL isolated from tumor digest from four patients
(biopsy tissue was examined in two out of the four patients).
Memory CD4+ Tconv cells and memory CD8+ T-cell subsets
were isolated by flow cytometric cell sorting and the TCRβ CDR3
region was sequenced (Fig. 5a and Supplementary Fig. 6a, b).
First, the clonality of CD4+ and CD8+ T cells in blood and
matching drLN samples pre- and post anti-OX40 was analyzed in
these patients. A clonality score of 1 indicates a monoclonal
population, whereas clonality values close to 0 indicate very
diverse, polyclonal populations. Peripheral CD4+ T cells from
HNOX05 and HNOX11 displayed a small increase in clonality,
whereas clonality decreased in HNOX04 and HNOX18 post
OX40. Clonality in the peripheral CD8+ T-cell compartment
increased in three out of the four patients after anti-OX40
treatment (Fig. 5b). Of note, CD4+ T-cell clonality in the TIL
increased twofold after anti-OX40 treatment; however, in DN, SP,
and DP CD8+ subsets clonality was unchanged (Fig. 5c), which
could be due to an influx of other CD8+ T-cells clones, thus
diluting clones that expanded in situ. To compare the distribution
of CD4+ and CD8+ T-cell clones within the tumor and per-
iphery, we used the Morisita–Horn index, which calculates clonal
overlap between two populations. TCRβ CDR3 sequences of
sorted peripheral memory CD8+ T cells were isolated from pre-
and post anti-OX40 samples. There was a significant overlap of
memory CD8+ T cells with both the DN and SP subsets but
much less with the DP CD8+ TIL (Supplementary Fig. 7a). By
focusing our analysis on the TIL subsets and drLN post treat-
ment, we found that TCR sequences from DN and SP subsets
overlap significantly in all four patients tested and share
sequences with the drLN CD8+ T cells (Fig. 5d, left and middle
panel). In contrast, DP TIL had a unique TCRβ repertoire
(no overlap between DN, SP, or drLN CD8+ cells) which may
have been the result of local intratumoral expansion, as suggested
by increased Ki-67 levels (Figs. 3e and 5d)27. To examine this
further, we evaluated the clonality within the DP CD8+ TIL
population and found that the top 30 clones accounted for
Fig. 4 Survival analysis of patients after neoadjuvant anti-OX40
administration. Patients were followed for disease-free (DFS) and overall
survival (OS). a Kaplan–Meier estimate of DFS (orange) and OS (blue). The
numbers below the graph represent the number of patients at risk. N= 17
head and neck squamous cell carcinoma (HNSCC) patients. Supplementary
Table 4b contains the survival estimate for the overall and disease-free
survival dataset as outlined in Gebski et al.31. b DFS in immune-responding
(N= 4, blue) vs non-responding (N= 13, orange) HNSCC patients. The log-
rank test (Mantel–Cox) was used to compare both curves and P values < 0.05
were considered statistically significant. Source data are provided as Source
Data file.
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76–96% of all CDR3 sequences, with the top three clones present
at frequencies above 30% (Supplementary Fig. 7b).
To better understand the relationship of T cells in the blood
and tumor before and after anti-OX40 treatment, we focused on
those top 30 clones in DN, SP, and DP CD8+ TIL subsets post
treatment and asked whether they were present in pretreatment
samples. Figure 5e separately depicts DN, SP, and DP subsets
from HNOX04 and HNOX18, and the frequencies of shared
clones in blood and tumor at baseline and DOS. In all subsets,
the frequency of clones in TIL is higher than in blood, and some
Fig. 5 TCRβ sequencing analysis reveals clonal differences following administration of anti-OX40. TCRβ sequencing was performed on blood and TIL
samples obtained before and after anti-OX40 administration. The gating strategy for the isolation of the blood and TIL subsets is outlined in Supplementary
Fig. 6a, b. a Schematic of all T-cell subsets that were isolated from blood and tumor by cell sorting, followed by DNA isolation and TCRβ sequencing.
b Summary of the clonality of CD4+ and CD8+ T cells in blood before anti-OX40 as well as blood and drLN at DOS in four patients. c Summary of the
clonality of CD4+ TIL and CD8+ TIL subsets (DN, SP, and DP) before (pre) and after (post) anti-OX40. N= 2 pre, N= 4 post. Error bars indicate mean ±
SEM in the post patients. d TCRβ repertoire overlap was calculated using the Morisita–Horn index. Overlap analysis is shown for DN CD8+ TIL compared
with SP, DP, and drLN cells. The same analysis was performed for SP CD8+ TIL (with DN, DP, and drLN) and DP CD8+ TIL (with DN, SP, and drLN).
Colors and symbols in (b) and (d) depict the four patients. e The top 30 clones in the DOS specimen (DN, SP, and DP) were separately compared to the
same subsets pretreatment and to memory CD8+ T cells in blood at D1 and D12. Black open circles represent the blood before and after anti-OX40,
orange filled circles represent the biopsy (pre) specimen, and red filled circles the DOS (post) specimen. Connecting lines indicate the presence of the
same TCRβ sequence in each subset. f Red filled circles represent the number of clones among the top 30 clones in DP CD8+ TIL post treatment, that
were present in the sample pretreatment. In b–f, N= 4 patients (HNOX04, HNOX05, HNOX11 and HNOX18) were analyzed. M memory, LN lymph node,
DOS day of surgery.
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clones increase or decrease differentially after anti-OX40
treatment. However, among the top 30 clones found in the
DP TIL post treatment, only eight and three clones were shared
with the peripheral T cells in HNOX04 and HNOX18,
respectively (Fig. 5f). Similar results were obtained for
HNOX05 and HNOX11 (three and eight clones, respectively)
(Supplementary Fig. 7c).
Lastly, we sought to determine whether the CD8+ TIL
recognized tumor antigens in patients that showed an immuno-
logic response as assessed by the activation index in Fig. 3a. We
sorted and expanded DN, SP, and DP CD8+ T cells from
HNOX04, HNOX07, and HNOX18 (all IR) and screened them
for neoantigen reactivity after predicting neoantigens based on
whole-exome and RNA-sequencing data. For HNOX18 (HPV+
patient), we did not detect reactivity of DN, SP, or DP CD8+
T cells to any of the predicted 133 mutated peptides we screened
(Supplementary Data 2). However, when DN, SP, and DP cells
from HNOX18 were screened against peptides from HPV16 and
HPV18 E6 and E7 proteins (tumor-associated antigens), we
observed a strong response to HPV16 E6 and E7 only in the DP
CD8+ T-cell subset (Fig. 6a, b). To investigate whether the HPV-
specific response was due to one or several T-cell clones, we
sorted 4-1BB-CD25- (non-reactive) T cells and 4-1BB+ CD25+
(reactive) T cells after 18 h coculture with HPV16 E6 and E7
transfected PBMC. Response to E6 was driven by four dominant
T-cell clones and response to E7 comprised two dominant T-cell
clones (clonality cutoff >2%) (Fig. 6c). For HNOX04 and
HNOX07 (HPV− IR), 85 and 29 potentially immunogenic
neoantigen peptides were predicted, respectively (Supplementary
Data 2). Reactivity to one unique neoantigen for each patient was
detected (Fig. 6d–g). Reactivity to a mutated peptide from SP100
(a tumor suppressor gene) was restricted to the DP CD8+ TIL
(Fig. 6d, e; HNOX04), whereas in HNOX07 there was reactivity
in both SP and DP cells to mutated PPP1R13L (inhibitor of p53)
(Fig. 6f, g). Together these data confirm that tumor-antigen-
specific T cells are enriched within the DP CD8+ TIL subset in
HNSCC patients. Since anti-OX40 was able to increase the
frequency of the DP CD8+ TIL subset in the immunologic
responder patients, we hypothesize that the increased frequency
of the tumor-reactive T cells after treatment aids in tumor
clearance and protection from recurrence (as demonstrated by
survival benefit in Fig. 4a, b).
Discussion
Here, we describe the results from a first-in-human neoadjuvant
clinical trial treating HNSCC patients with an OX40 agonist
antibody and the subsequent immunologic changes in tumors
and peripheral blood after drug infusion. Administration of
anti-OX40 (MEDI6469) prior to surgery was safe, did not delay
surgery, and resulted in no unexpected surgical complications.
We observed immune activation illustrated by increased CD4+
and CD8+ T-cell proliferation following treatment, which
peaked between 2 and 3 weeks after antibody infusion. Impor-
tantly, we also demonstrated that anti-OX40 increased clonality
in the peripheral blood CD8+ T-cell compartment and clonality
of tumor-infiltrating CD4+ cells of some patients. Expansion of
tumor-antigen-specific CD103+ CD39+ CD8+ TIL was
observed in 4 of 16 patients with evaluable pre- and post-
treatment samples. Understanding why the expansion of the DP
CD8+ TIL occurred in only 25% of patients will require further
investigation, but may be related to the presence of negative
regulatory elements within the tumor (e.g., Treg cells, myeloid-
derived suppressor cells, TGF-β, expression of checkpoint
ligands). Hence, blocking negative immune regulators or factors
while boosting OX40 signaling may lead to greater CD8+ TIL
activation in a larger fraction of patients. Despite considerable
enthusiasm for anti-OX40 based on our initial phase I trial24,
humanized OX40 agonists have not exhibited significant clinical
activity when used as monotherapy or in combination with
checkpoint inhibition. Lack of efficacy might be related to
schedule and dosing33,34. While adequate for checkpoint pro-
teins, dosing 2–3 weeks apart may not be optimal for agonist
antibodies. Of note, preclinical data and data in our clinical
trials demonstrated immune activation and tumor reduction
after short pulses of anti-OX40 (given 2–3×/week)24,35.
Much work has been devoted to the analysis and character-
ization of the treatment-naive tumor microenvironment, so as to
inform patient care and possibly a response to therapy. However,
obtaining study material can be challenging, and therefore detection
of biomarkers in peripheral blood to predict response would be
ideal. Immune activation in peripheral CD4+ and CD8+ T cells
peaked between D12 and D19 after anti-OX40 and these cells were
characterized by high expression of ICOS, Ki-67, and CD38.
Patients in the D8 cohort might have exhibited a similar increase in
peripheral blood immune activation at a later time, however, the
trial was not designed to include additional blood draws at 4- or 11-
days post surgery. In a future study, additional timepoints will be
included. The expansion cohort was informed based on increased
proliferation between D12 and D19 and D12+/− 2-day patients
were accrued for the remainder of the trial, with the exception of
patient HNOX16, whose surgery was delayed and thus included in
the D19 cohort. Data from the Sharma laboratory in both pre-
clinical models as well as patients with bladder cancer, prostate
cancer, and metastatic melanoma suggested that increased ICOS
protein expression on CD4+ T cells was indicative of a response to
CTLA-4 treatment10,36–39. In our patients, ICOS upregulation on
peripheral CD4+ cells did not distinguish immune responders and
non-responders (Supplementary Fig. 5b). Hence, we believe that
ICOS alone as a biomarker on CD4+ cells is not sufficient to
differentiate robust immune responses to anti-OX40; however, a
combination of ICOS with an activation marker, such as 4-1BB or
CD40L, may help segregate patients into immunologic responders
versus non-responders. In future studies, high-dimensional multi-
parameter blood profiling using CYTOF and/or state-of-the-art
flow cytometry approaches might aid in finding immune-based
biomarkers of response.
Preclinical data from our laboratory has shown that anti-OX40
was superior to CTLA-428 in its ability to enhance the pro-
liferation and survival of vaccine-stimulated T cells. We and
others have also demonstrated that anti-OX40 can reinvigorate
exhausted/anergic T cells and promote priming and maintenance
of tumor-antigen-specific CD8+ cells in the periphery40,41. In
line with this observation, Crittenden et al. showed in a mouse
model that tumor-activated T cells generated after tumor
implantation are critical for the T-cell response subsequent to
radiation and checkpoint inhibition42. Based on these data, and
results from our trial, we hypothesize, that anti-OX40 not only
increases the priming of peripheral T cells to tumor antigens but
also boosts pre-existing tumor-antigen-specific T cells. When
followed by PD-1 blockade, this combination could limit T-cell
exhaustion within the tumor, resulting in improved tumor con-
trol. Several laboratories, including ours, have addressed this
critical question in preclinical studies and, while the sequence of
administration and dosing appears to be dependent on respective
mouse models, combined treatment of anti-OX40 with check-
point blockade has shown greater anti-tumor activity33,34,43.
In the tumor, we focused our analysis on a population of
tumor-resident CD8+ T cells that we have shown are highly
enriched for tumor–antigen reactivity27. With access to tumor
specimens before and after anti-OX40, we found an increase in
CD8+ CD103+ CD39+ cells in the tumor in 4 of 16 patients
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(3 HPV−, 1 HPV+) after anti-OX40 infusion and none of these
patients have had a tumor recurrence. Twelve of 16 patients
(7 HPV−, 5 HPV+) displayed less dramatic changes within the
DP CD8+ TIL and 5 have recurred thus far (with one death).
Therefore, seven patients that failed to exhibit an increase in
our activation index are still tumor-free. This could be due to
timing—D8 patient samples (blood and TIL) were taken prior to
the peak in immune activation—or the tumor microenvironment
in these tumors was more suppressive and prevented infiltration
and/or expansion of CD103+ CD39+ CD8+ TIL.
TCR diversity, which is often used as a surrogate for immune
competence, has been investigated in many immune-oncology
clinical trials. We analyzed the T-cell repertoire in sorted T-cell
subsets from DOS specimens and blood before and after anti-
OX40 treatment in four patients, two of whom we also obtained
a biopsy prior to anti-OX40 dosing. Using sorted cells allowed
us to discriminate CD4+ Tconv, Treg, and CD8+ cells and
more specifically, to distinguish tumor-specific cells (DP) from
bystander cells (DN, SP) which are abundant in some tumors44.
T-cell clones in both patients increased up to 15-fold after
Fig. 6 Identification of neoantigen and HPV-reactive cells in patients after anti-OX40. Expanded DP CD8+ T cells from HNOX18 were screened for
reactivity against HPV16, and neoantigens were predicted for HNOX04 and HNOX07. Peptide Pools were screened for reactivity by IFN-γ -ELISpot
analysis. a Expanded DP CD8+ T cells from HNOX18 were screened with autologous PBMC transfected by electroporation with RNA encoding HPV16 E6
and E7 proteins. Anti-CD3 is a positive control, water the negative (MOCK) control. Prior to IFN-γ ELISpot development (right), cells were harvested and
expression of 4-1BB and CD25 was assessed by flow cytometry (left). b Summary of HPV-specific spot-forming cells (SFC) in CD8+ TIL subsets. c HPV16
E6 and HPV16 E7 reactive CD8+ T cells were sorted based on the expression of 4-1BB and CD25. 4-1BB-CD25− and 4-1BB+ CD25+ cells were analyzed
by TCRβ-sequencing and the frequency of the top 6 (E6) and top 7 (E7) clones are depicted. d Expanded DP CD8+ T cells from patient HNOX04 were
screened with the addition of predicted neoantigens. Shown is the response to peptide 5, anti-CD3 as positive, DMSO as the negative control. e Summary
of spot-forming cells (SFC) in CD8+ TIL subsets from HNOX04. f Expanded DP T cells from HNOX07 were screened with the addition of predicted
neoantigens. Shown is the response to peptide 21, anti-CD3 as positive, DMSO as the negative control. g Summary of SFC in CD8+ TIL subsets from
HNOX07. Red depicts the peptide response, gray is the anti-CD3 control, black the MOCK/DMSO control. TMG tandem minigene. Source data are
provided as Source Data file.
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anti-OX40; however, the DP subset exhibited the highest and
most robust increases compared to DN and SP cells (Fig. 5f). To
address whether DP CD8+ TIL were enriched for tumor- or
tumor-associated antigen reactivity, we tested the reactivity of
DN, SP, and DP TIL to neoantigens for three patients. While an
HPV-specific and a neoantigen-specific T-cell response were
found in 2/3 patients exclusively within the DP TIL population,
the reactivity for one neoantigen was also found in both the DP
and SP CD8 TIL in one patient (HNOX07). These tumor
antigen-specific T cells within the CD103 SP TIL may not have
upregulated CD39 and/or expressed lower levels of CD39 at the
time of surgery. Based on our previous publication27, we also
believe that the high-frequency clones (Supplementary Fig. 7b)
within the DP TIL fraction in HPV− patients are most likely
tumor antigen-specific, but were not detected as such using
our mutated short peptide/MHC I binding algorithm approach.
In collaboration with a group in the Netherlands, we showed
that in colon cancer patients, reactivity to neoantigens was
confined to the CD103+ CD39+ CD8+ TIL45. Recent
studies have highlighted limitations in current mutated antigen
pipelines suggesting that intronic regions could contribute
to the neoantigen pool46 and some of the T-cell responses
could be directed to overexpressed self-antigens. Furthermore,
depending on the tumor type and the intrinsic tumor-
reactivity of the intratumoral TCR repertoire, the capacity to
recognize autologous tumor can vary substantially47 and those
biologic and technical limitations will be addressed in future
studies.
In summary, we have shown that anti-OX40 delivered in the
neoadjuvant setting has few side effects and does not delay sur-
gical resection in HNSCC patients. Extensive immune monitoring
demonstrated that the majority of patients exhibited evidence of
increased peripheral blood CD4+ and CD8+ T-cell activation
and proliferation, with a subset of patients showing the expansion
of CD103+ CD39+ CD8+ TIL, which are enriched for tumor-
reactivity, and correlate with greater disease-free survival. Our
group has recently initiated a clinical trial testing a humanized
OX40 agonist (MEDI0562) in the neoadjuvant setting in HNSCC
and melanoma patients, which will allow us to assess the agonist
activity of an anti-OX40 antibody independent of anti-drug
immune responses. In parallel, we are investigating multiple
factors that may limit immune responses in cancer patients
treated with anti-OX40, which should reveal ways to enhance
tumor antigen-specific T-cell function in a greater number of
patients.
Methods
Patients. Eligible patients were 18 years of age or older and had stage II, III, or IVA
HNSCC that was considered surgically resectable. All patients had an Eastern
Cooperative Oncology Group (ECOG) performance-status score of 0 or 1.
Exclusion criteria were immunodeficiency, ongoing systemic immunosuppressive
therapy, active autoimmune or infectious disease, clinically significant concurrent
cancer, and medical or psychiatric condition that in the opinion of the PI would
preclude compliance with study procedures.
Study design. This two-stage study (PH&S IRB # 14-042, NCT02274155) started
with a Phase Ib time interval reduction design with a constant anti-OX40 dose
based on the previous Phase I trial. The stage I portion of the study was to include
at least nine patients with a six patient safety run. The second stage would include
an expansion cohort of up to 21 additional patients in the cohort selected, based on
the most promising immune response in peripheral blood and within tumors of
patients enrolled in stage I. No statistical tests were performed to calculate the
sample size. Eligible patients were registered and provided written informed con-
sent, after which they were assigned to a cohort based upon practical scheduling
and patient desire (no randomization):
Cohort 1: anti-OX40 0.4 mg/kg IV d1,3,5, surgery 2 weeks later (d17–21)
Cohort 2: anti-OX40 0.4 mg/kg IV d1,3,5, surgery 1 week later (d10–14)
Cohort 3: anti-OX40 0.4 mg/kg IV d1,3,5, surgery 2–3 days later (d7–8)
The primary endpoint was a delay in time to surgery; secondary endpoints
included exploratory assessments to determine the timing of peak immunologic
effect and to compare the composition and immunologic phenotypes of TIL
subsets before and after anti-OX40 administration. The first patient was enrolled
on December 5, 2015 (HNOX01), and the last patient was enrolled on April 17,
2017 (HNOX19). All patients were monitored for adverse events, according to the
National Cancer Institute Common Terminology Criteria for Adverse Events,
version 4.0. Patients were deemed ineligible if planned surgery was delayed more
than 3 days. All patients underwent the following: baseline tumor staging with a
contrast-enhanced CT or magnetic resonance imaging of the neck and chest;
positron-emission tomography–computed tomography (PET–CT); and a
pretreatment biopsy of the primary tumor or metastatic lymph node, a portion of
which was harvested as a fresh research specimen for flow cytometric analysis.
Resection of the primary tumor, metastatic, and draining lymph nodes was
completed as part of the standard of care and appropriate microvascular
reconstruction was performed as indicated. All patients were offered conventional
adjuvant risk-adapted radiotherapy or chemoradiotherapy per NCCN guidelines
and were followed for recurrence-free and overall survival.
Clinical assessments. Anti-OX40 was infused at 0.4 mg/kg IV over 60 min for
three doses, 48–96 h apart. The timing of surgery and number of assessments
between anti-OX40 and surgery depended on cohort assignment. Repeat neck CT
to assess changes in tumor volume for surgical planning purposes was performed
pre-operatively at the discretion of the treating physician. Peripheral blood draws
to assess immune parameters were mandatory on day 1, day 12+/− 2d, day 34+/−
3d, and day 55+/− 7d of the study. A research nurse performed an autoimmune
disease assessment on day 1, day 12+/− 2d, day 34+/− 3d, and day 55+/− 7d.
Pregnancy testing with b-HCG was mandatory on day 1 of treatment for pre-
menopausal females. Follow-up after day 55+/− 7d (the completion of the study)
was dictated by the clinical response. Patients had a physical exam, interval ima-
ging every 3 months and for the first 2 years following surgical treatment, and every
6 months thereafter per treating MD recommendations. Another treatment as
deemed medically appropriate was offered to patients with disease progression.
All survival endpoints for immunologic responders versus non-responders were
calculated from the day of surgery.
Trial oversight. This study was approved by the institutional review board at
Providence Health and Services-Oregon. The study was designed, and the paper
was written by the authors, who are responsible for the accuracy of its content. The
trial was conducted in accordance with the ethical principles of the Declaration of
Helsinki and with adherence to the Good Clinical Practice guidelines, as defined by
the International Conference on Harmonization. The study also complies with the
ICMJE guidelines on reporting. MEDI6469 (clone 9B12) was supplied by Med-
Immune; 9B12 is a murine IgG1, anti-OX40 monoclonal antibody (mAb) directed
against the extracellular domain of human OX40 (CD134) and was administered at
0.4 mg/kg on days 1, 3, and 5. The company did not have another role in the study
or the report.
Survival data and statistical analysis. Overall- and disease-free survival were
calculated from the date of surgery until last contact or death or disease recurrence,
respectively, using the Kaplan–Meier method. The reverse Kaplan–Meier method
was used to calculate median follow-up30. The number at risk was presented as a
supplementary table for overall and disease-free survival as outlined in Gebski
et al.31. Immunologic, histologic, and genomic analyses were performed on selec-
ted/available biospecimens, and correlative data were analyzed as described in the
respective sections. A generalized estimating equation (GEE) model48,49 was uti-
lized to compare measurements over time in order to account for correlation
among repeated measures from the same subject. Correlation structures including
exchangeable, autoregressive with order 1 or AR (1), and independence were
evaluated using quasi-likelihood under the independence model for the criterion
(QIC) for analysis. The exchangeable model was selected for the GEE and reported
in Supplementary Data 3. Statistical significance between baseline and D12 or D19
was determined by paired Student’s t test or the mixed-effects model and Tukey
multiple comparison test using GraphPad Prism 8 software (GraphPad, San Diego,
CA). Reported P values are two-sided, and the significance level was set at 0.05 for
all analyses unless otherwise noted.
Patient samples. Peripheral blood, uninvolved LNs, metastatic LNs, and tumor
samples were obtained from all HNSCC patients. All subjects signed written
informed consent approved by the Providence Portland Medical Center Institu-
tional Review Board (PH&S IRB # 14-042). At the time of enrollment, patients
were not undergoing therapy. PBMC were purified from whole blood over Ficoll-
Paque PLUS (GE Healthcare) gradient and cryopreserved prior to analysis. Tumor
specimens were prepared as follows: Under sterile conditions, tumors were cut into
small pieces and digested in RPMI-1640 supplemented with hyaluronidase at
0.5 mg/ml, collagenase at 1 mg/ml (both Sigma-Aldrich), DNase at 30 U/ml
(Roche) as well as human serum albumin (MP Biomedicals) at 1.5% final con-
centration. Cells were digested for 1 h at room temperature under agitation with a
magnetic stir bar. Cell suspensions were filtered through a 70-μm filter. TIL were
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enriched as described above by Ficoll-Paque PLUS density centrifugation. Tumor
single-cell suspensions were cryopreserved in LN2 until further analysis.
Antibodies and flow cytometry. Fresh blood and cryopreserved samples were
used for flow cytometry studies.
The following fluorescent-labeled antibodies were used in various
combinations: allophycocyanin (APC)-Cy7 and brilliant violet (BV) 605 anti-CD3
(UCHT1; 1:100—#300426 and #300406, respectively), BV785 anti-CD4 (OKT-4;
1:200—#317442), BV510 anti-CD8 (RPA-T8; 1:100—#301048), PerCP/Cy5.5 anti-
CD19 (HIB19; 1:50—#302230), BV650 anti-CD25 (BC96; 1:100—#302634), APC
and Alexa Fluor (AF) 488 anti-CD38 (HIT2; 1:50—#303510 and #303512,
respectively), AF700 and BV711 anti-CD45RA (HI100; 1:50—#304120 and
304137), BV605 anti-CD69 (FN50; 1:50—#310938), BV421 anti-CD127 (A019D5;
1:50—#351310), PE-Cy7 anti-PD-1 (EH12.2H7; 1:50—#329918),PE-Cy7 anti-4-
1BB (4B4-1; 1:40—#309818), PE/Dazzle 594 anti-CCR7 (G043H7; 1:50—#353236),
BV711 anti-HLA-DR (L243; 1:100—#307644), BV510 anti-IgD (IA6-2; 1:50—
#348220) (all from Biolegend); PE-CF594 anti-CD24 (ML5; 1:50—#562405),
BV421 anti-CD27 (M-T271; 1:50—#562513), FITC anti-CD127 (HIL-7R-M21;
1:10—#560549), PE anti-OX40 (ACT35; 1:40—#555838), PE-Cy7 anti-PD-1
(EH12.1; 1:50—#561272), PE anti-granzyme B (GB11; 1:200—#561142), AF 488
and PE anti-Ki-67 (B56; 1:100—#561165 and 1:50 #556027) (all from BD
Biosciences); APC-efluor780 anti-CD8 (RPA-T8; 1:100—#47-0088-42), APC and
PE-Cy7 anti-CD39 (eBioA1; 1:100—#17-0399-42 and #25-0399-42, respectively),
PE and PerCP-efluor710 anti-CD103 (B-Ly7 and Ber-ACT8; 1:100—#12-1038-42
and 1:50—#46-1037-42, respectively), efluor450 and AF700 anti-Foxp3 (PCH101;
1:40—#48-4776-41 and 1:25—#56-4776-41, respectively), biotinylated anti-ICOS
(ISA-3; 1:100—#13-9948-82), Streptavidin APC-efluor780 (1:100—#47-4317-82)
(all from eBioscience); A fixable live/dead dye was used to distinguish viable cells
(Biolegend). Cell surface staining was performed in FACS buffer (PBS,
supplemented with 1% FBS and 0.01% NaN3). Intranuclear staining was performed
using the Fix/Perm kit from eBioscience according to the manufacturer’s
instructions.
Stained cells were acquired on an LSRII and LSRFortessa flow cytometer, the
FACS AriaII (all BD Biosciences) for cell sorting, and the Attune Nxt flow
cytometer (Thermo Fisher Scientific). Data were acquired using FACS Diva and the
Attune Nxt flow cytometer software, respectively. Data were analyzed with FlowJo
software (Treestar).
Cell sorting and T-cell expansion. Cryopreserved PBMC and TIL were thawed
and enriched for T lymphocytes using the T-cell enrichment kit from Stemcell for
ex vivo staining. For TIL enrichment, EpCAM beads (StemCell) were added to the
cocktail. The enriched fractions were then labeled and populations of interest were
purified after cell sorting to 99% purity on a FACSAria II. Briefly, naive CD8+
T cells were sorted as CD8+CD4−CD45RA+CCR7+ cells and memory CD8+
T cells were sorted as CD8+CD4−CD45RA−CCR7+/− (total memory). Naive
CD4+ subsets were sorted as CD4+ CD8−CD45RA+CCR7+ Foxp3-CD25- cells
and memory CD4+ T cells in blood and PBMC were sorted as CD4+
CD8–CD45RA−CCR7+/− Foxp3- (total memory). CD8+ subsets from TIL were
sorted as CD3+CD4−CD8+CD45RA−CCR7+/−CD39−CD103−(DN), CD3+
CD4−CD8+CD45RA−CCR7+/−CD39−CD103+ (SP), and CD3+CD4−CD8+
CD45RA−CCR7+/−CD39+CD103+ (DP). For TCR sequencing analysis, cell pellets
were frozen after cell sorting until further processing.
For the expansion of DN, SP, and DP CD8+ TILs as well as naive and memory
CD8+ T cells, cells were sorted and cultured in complete RPMI-1640,
supplemented with 2 mM glutamine, 1% (vol/vol) nonessential amino acids, 1%
(vol/vol) sodium pyruvate, penicillin (50 U/ml), streptomycin (50 μg/ml), and 10%
fetal bovine serum (Hyclone) or 10% pooled human serum (in house preparation).
Of note, for functional assays and expansion, no CD3 antibody was used for cell
sorting. Sorted T cells were stimulated polyclonally with 1 μg/ml
phytohemagglutinin (PHA) (Sigma) in the presence of irradiated (5000 rad)
allogeneic feeder cells (PBMC; 2 × 105 cells per well) and 10 ng/ml of interleukin
(IL)-15 (Biolegend) in a 96-well round-bottom plate (Corning/Costar). T-cell lines
were maintained in complete medium with IL-15 until analysis.
DNA preparation and TCRβ sequencing. Sequencing of the variable V–J or
V–D–J regions of TCRβ genes was performed on genomic DNA of sorted T-cell
populations. DNA was extracted from circulating and tumor-resident CD8+ and
CD4+ T-cell subsets ex vivo, and expanded T cells (for tumor reactivity studies), at
numbers ranging from 1 × 104–1 × 105 cells (DNeasy Blood and Tissue Kit, Qia-
gen). The TCRβ CDR3 regions were sequenced and mapped using the human
hsTCRB sequencing kit (ImmunoSEQ, Adaptive Biotech). Samples were sequenced
using a MiSEQ sequencer (Illumina). Coverage per sample was >10×. Only data
from productive rearrangements were extracted from the ImmunoSEQ Analyzer
platform for further analysis. Clonality of the different T-cell subsets was assessed
by nucleotide sequence comparison of all clones in each subset. To compare the
TCR Vβ overlap (or similarity) of two given populations, we used Morisita’s
overlap index. For the comparison of shared clones between subsets, we analyzed
the top 30 clones in each subset.
Whole-exome sequencing (WES). For each FFPE tumor specimen, eleven 5-µm
slides were cut from the FFPE block for histopathological and genome sequencing.
One slide was stained with hematoxylin and eosin and was reviewed by a board-
certified pathologist to identify regions of high tumor purity. These regions were
then macrodissected from the corresponding ten unstained and deparaffinized
slides and pooled for DNA and RNA coextraction. DNA and RNA purification was
performed on an automated QiaCube instrument using DNA/RNA AllPrep
reagents (Qiagen) according to the manufacturer’s instructions. Corresponding
normal DNA for germline exome testing was purified from peripheral blood
mononuclear cells (PBMC) as above. DNA and RNA were quantified using a Qubit
fluorometer (Thermo Fisher).
WES for tumor and germline specimens was performed on purified DNA as
follows: DNA was prepared into tagged sequencing libraries using Kapa HyperPlus
library preparation reagents (Roche) and exome hybrid-capture was performed
using the xGen Research Panel kit (IDT). Captured library pools were normalized
and loaded onto a HiSeq 4000 sequencer (Illumina) for next-generation
sequencing. WES reads were aligned to Genome Reference Consortium Human
Build 37 (hg19) followed by GATK preprocessing. Somatic mutation calling was
performed using Mutect, Somaticsniper, Strelka, and Varscan. Initial filtering
criteria consist of >10 tumor exome reads, >10 germline exome reads ≥10%
variant-allele frequency (VAF) in the tumor exome, >10 normal reads, tumor/
normal variant frequency ≥5. Somatic mutations that passed the filters were further
annotated with 1000 genomes project, Exome Aggregation Consortium (ExAC),
The Catalogue of Somatic Mutations In Cancer (COSMIC) databases using
Annovar and SNPeff was used to predict the variant functional effect. Every
mutation found to have a protein-coding change was used to build putative
neoepitopes of 25-mer amino acid sequence.
Paired tumor/germline whole-exome aligned BAM files along with five other
tumor and germline samples from different cases were loaded into Integrative
Genomics Viewer (Broad Institute) to perform validation of identified
nonsynonymous mutations and to filter potential sequencing artifacts. Mutations
that are identified by ≥2 (of 4) mutation callers were manually interrogated.
Potential 25-mer neoantigen sequences that passed the above filters were converted
into FASTA format and run through NetMHCpan 4.0 Server (Technical University
of Denmark). NetMHCpan generated 8–11mer peptides from the 25-mer
neoantigen sequence and predicted binding affinity to patient-specific MHC Class-
I molecules. Peptides predicted to have a binding affinity ≤0.5 nM were considered
candidates for further evaluation. Those peptides were synthesized by GenScript
USA Inc. and subsequently tested for reactivity against patient CD8+ T-cell
subsets. The predicted mutated antigens used for reactivity screening are available
in Supplementary Data 2. WES data are not publicly available due to HIPAA
protection of the patients’ germline sequencing data.
RNA sequencing. RNA purified from FFPE tissues was prepared into RNA-seq
libraries using RNA Access Library Preparation reagents (Illumina) according to
the manufacturer’s instructions. RNA-seq libraries were assessed for quantity and
quality by TapeStation (Agilent) and QuBit (Thermo Fisher). Libraries were pooled
and sequenced at a depth of 25–50 million reads on a HiSeq 4000 sequencer
(Illumina). RNA alignment was performed using STAR alignment, duplicate reads
were marked using Picard’s Mark Duplicate tool, and fragments per kb per million
mapped reads (FPKM) values were calculated using cufflinks. FPKM levels were
used to assess the expression of candidate mutations that are identified using
whole-exome data. In select cases, candidate neoepitopes with transcript levels
exceeding 100 FPKM were prioritized.
Patients did not provide consent to release read-level RNA-sequencing data
containing private/rare variants, but de-identified datasets are available upon
request.
Human papillomavirus (HPV)-specific gene production. To screen for recog-
nition of HPV tumor antigens, four constructs were used, encoding for the full-
length amino acid sequences of HPV (type 16 and 18) E6 and E7 oncoproteins
(159, 99, 159, and 106 aa, respectively). They were cloned into pcDNA3.1+CEF-
MHC-1-v2 using HindIII and BamHI restriction sites and flanked with
AAGCTTGCCACC (5′) and GGATCC (3′) using GenScripts service. Following
linearization of the constructs, DNA was cleaned up using a DNA Cleanup &
Concentrator kit (Zymo Research). Next, we used 1 μg of linearized DNA to
generate in vitro–transcribed (IVT) RNA using the Mmessage Mmachine T7 Ultra
kit (Life Technologies) as instructed by the manufacturer. RNA was cleaned up
(Zymo Research) and concentration determined prior to use in transfections.
Transfection of HPV RNA. Cryopreserved autologous PBMC were resuspended in
Opti-MEM (Life Technologies) at 10 × 106 to 30 × 106 cells/ml. In total, 2 µg of
HPV RNA was added to a 2-mm gap electroporation cuvette, followed by 50 µl of
PBMC. Cells were electroporated at 250 V for 5 ms for one pulse, using a BTX
ECM 830 Square Wave Electroporation System (Harvard Bioscience Inc.). Elec-
troporated PBMC were washed and resuspended in complete medium at 1.3 ×
106–2.5 × 106 cells/ml. In total, 100 µl volumes of electroporated PBMC were co-
cultured with CD8+ T-cell subsets in an ELISpot assay on the same day.
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IFN-γ enzyme-linked immunospot (ELISpot) assay and detection of activation
markers by flow cytometry. The immunogenicity of predicted neoepitopes and
HPV antigens against sorted CD8+ T-cell populations (DN, SP, DP) was assessed
via paired ELISpot assay and detection of activation markers (CD25, 4-1BB, PD-1,
Granzyme B) by flow cytometry. The PVDF membrane on ELIIP plates (Millipore,
MAIPSWU10) was activated by adding 70% ethanol, 50 µl per well, for 2 minutes.
Wells were washed 5× with PBS and then coated with 50 µl of 10 µg/ml IFN-γ
capture antibody (Mabtech, clone: 1-D1K) overnight. For OKT3 controls, wells
were coated with a mixture of IFN-γ capture antibody (10 µg/ml) and OKT3
(1 µg/ml). Cryopreserved T-cell subsets were thawed and rested overnight at 37 °C
in complete medium supplemented with IL-15 (10 ng/ml). T cells were washed,
and 1 × 105 T cells were added per well to a 96-well plate. In initial screenings
evaluating mutated antigen recognition, peptides were pooled (12 peptides per
pool) and added to wells at a final concentration of 1.25 µg/ml. In subsequent
screenings, reactive pools were deconvoluted and single peptides were added to
wells at 2 µg/ml. Prior to coculture, the plates were washed 1× with PBS, followed
by blocking with complete RPMI media for at least 1 h at room temperature. T-cell
and peptide cocultures were carried out for 20 h. In HPV-specific T-cell recogni-
tion assays, 100 µl of electroporated PBMC were added to T cells and transferred to
an ELIIP plate. Following coculture, cells were harvested and assessed via flow
cytometry for upregulation of activation markers. ELIIP plates were washed 6×
with PBS+ 0.05% Tween-20 (PBS-T) and then incubated for 2 h at room tem-
perature with 100 μl per well of a 0.22 μm-filtered 1 μg/ml biotinylated anti-human
IFN-γ detection antibody solution (Mabtech, clone: 7-B6-1, diluent consisted of 1×
PBS supplemented with 0.5% FBS). The plate was then washed 3× with PBS-T,
followed by 1 h incubation with 100 μl per well of streptavidin-ALP (Mabtech,
diluted 1:3000 with above diluent). The plate was washed 5x with PBS followed by
development with 100 μl per well of 0.45-μm-filtered BCIP/NBT substrate solution
(KPL, Inc.). The reaction was stopped by rinsing thoroughly with cold tap water.
ELISpot plates were scanned and counted using an ImmunoSpot plate reader and
associated software (Cellular Technology Limited). A well was considered positive
for T-cell reactivity if >100 spot-forming cells (SFCs) were present, as assessed by
the SmartCount function in ImmunoSpot software.
Pathologic analysis and multiplex IHC. Primary HNSCC tumor and lymph-
node specimens were for evaluated for tumor size and the presence or absence of
lymph-node metastases and staged according to the criteria of the American
Joint Committee on Cancer (AJCC, seventh & eighth edition). H&E staining was
performed on all tissue slides. To prepare specimens for multiplex IHC, tissue
sections were cut at 4 µm from formalin-fixed paraffin-embedded blocks. All
sections were deparaffinized, subjected to heat-induced epitope retrieval, and
stained with the Leica Bond RX autostainer. Two multiplex IHC panels were
performed on two consecutive tissue slides using the antibodies listed in Sup-
plementary Table 5. Antigen–antibody binding was visualized with the TSA-
Opal reagents from PerkinElmer. Antigen retrieval treatment was performed
between antibody detection to prevent cross-reactivity. Tissue slides were
incubated with DAPI as a counterstain and coverslipped with VectaShield
mounting media (Vector Labs). Control tissue samples were stained for each
marker separately.
Cell quantification in high-resolution images. Digital images were captured with
the PerkinElmer Vectra-Polaris platform following hot spot lymphocyte assess-
ment: Areas in the tumor-stroma interface were scanned at ×20 and selected for
analysis. We obtained six images of 0.36 mm2 each per tissue sample for analysis.
Multiplexed images were analyzed with InForm Software (PerkinElmer). The total
number of cells per mm2 was enumerated for all the cell phenotypes expressed in
the stroma and the tumor compartment. Tissue samples stained by conventional
H&E were scanned with the Leica SCN400F platform at ×20 and magnified at
×200–400 for immune infiltrate evaluation.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the TCR sequencing data have been deposited in the
ImmuneACCESS database (Adaptive Biotechnologies) under the https://doi.org/
10.21417/RD2020NC and URL clients.adaptivebiotech.com/pub/duhen-2020-nc. The
study protocol referenced in this study is available as Supplementary Data 1. The
predicted mutated antigens are available as Supplementary Data 2. Underlying WES
sequencing data are not publicly available due to HIPAA protection of the patients’
germline sequencing data. We do not have patient consent to release read-level RNA-
sequencing data containing private/rare variants. Any inquiries for accessing these data
(including RNA-sequencing data) should be directed to eacri.
bioinformatics@providence.org and we will grant access to the de-identified datasets for
research purposes. Supporting statistical documentation is summarized in
Supplementary Data 3. All the other data supporting the findings of this study are
available within the article and its supplementary information files and from the
corresponding authors upon request. Source data are provided with this paper.
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